Sam Brusco, Associate Editor08.10.22
NuVasive’s chief commercial officer, Massimo Calafiore, will resign from the company effective August 31.
According to the company, he will be departing NuVasive to become the CEO of a privately-held orthopedic technology company. Upon his resignation, Calafiore’s responsibilities will be reallocated among management while the company aligns commercial structure to long-term strategy.
"On behalf of the NuVasive team, I would like to thank Massimo for his impact on our organization," Chris Barry, NuVasive CEO told the press. "He has accomplished much during his tenure at NuVasive and we wish him great success in his new opportunity."
Calafiore stated, "In my five years at NuVasive, I am very proud of our collective work to transform surgery, advance care and most importantly—change the lives of patients around the world. NuVasive is an amazing company, and I'm excited to see what it will accomplish through bringing world-class, innovative technology to market."
According to the company, he will be departing NuVasive to become the CEO of a privately-held orthopedic technology company. Upon his resignation, Calafiore’s responsibilities will be reallocated among management while the company aligns commercial structure to long-term strategy.
"On behalf of the NuVasive team, I would like to thank Massimo for his impact on our organization," Chris Barry, NuVasive CEO told the press. "He has accomplished much during his tenure at NuVasive and we wish him great success in his new opportunity."
Calafiore stated, "In my five years at NuVasive, I am very proud of our collective work to transform surgery, advance care and most importantly—change the lives of patients around the world. NuVasive is an amazing company, and I'm excited to see what it will accomplish through bringing world-class, innovative technology to market."